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 Post-menopausal women with an intact uterus receive combined dose of estrogen 
and progestin during hormone replacement therapy (HRT) to reduce clinical 
symptoms such as hot flashes. Progestins, which include natural and synthetic 
compounds that have progesterone like activities, are added to reduce the known 
proliferative effects of estrogens on uterine cells that increase the risk of uterine 
cancer. Unfortunately, recent clinical trials have unexpectedly shown that progestins 
increase the incidence of breast cancer in women. Our laboratory has recently shown 
for the first time that the natural hormone progesterone can cause proliferation of 
breast cancer cells in vivo in an immunodeficient mouse model.  Therefore, we 
hypothesized that synthetic progestins used in clinics have the ability to increase 
proliferation of breast cancer cells.  To prove or disprove our hypothesis we injected 
6-week old immunodeficient mice subcutaneously with estrogen pellets, which 
continuously release estradiol, without which tumor cells cannot be retained. After 48 
h BT-474 human breast cancer cells were injected on both flanks of these mice.  The 
mice were then treated with 10 mg/60 day release pellets that contained the most 
commonly used synthetic progestin medroxyprogesterone acetate (MPA), norgestrel 
or norethindrone, and tumor volumes were measured over 30-60 days.  Our 
experimental data shows that all the synthetic progestins increased tumor growth in 
vivo. Thus we conclude that synthetic progestins increase proliferation of human 
breast cancer cells in vivo resulting in tumor expansion, and we suggest that caution 
should be exercised when prescribing synthetic progestins for treatment of post-
menopausal symptoms in women. 
 
